<DOC>
	<DOCNO>NCT00240162</DOCNO>
	<brief_summary>The purpose study evaluate efficacy PTK787/ZK 222584 , induce least 50 % reduction paraprotein patient multiple myeloma whose paraprotein level &lt; 5 g/dL follow high dose chemotherapy ( HDCT ) autologous stem cell transplantation ( ASCT ) .</brief_summary>
	<brief_title>PTK/ZK Post Transplant Maintenance Therapy Patients With Multiple Myeloma</brief_title>
	<detailed_description>To evaluate efficacy PTK787/ZK 222584 , induce least 50 % reduction paraprotein patient multiple myeloma whose paraprotein level &lt; 5 g/dL follow high dose chemotherapy ( HDCT ) Autologous Stem Cell Transplantation ( ASCT ) . To assess time progression disease free survival patient treat PTK787/ZK 222584 . To assess safety tolerability PTK787/ZK 222584 multiple myeloma patient follow ASCT .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Vatalanib</mesh_term>
	<mesh_term>Angiogenesis Inhibitors</mesh_term>
	<criteria>Patients eligible trial diagnose multiple myeloma standard criterion treat HDCT ASCT protocols Washington University School Medicine . Following HDCT ASCT patient must : 1 . Mcomponent ( IgG IgA ) persistent measurable paraprotein , &gt; =2 g monoclonal protein 24 hr urine specimen patient abnormal serum kappa/lambda ratio level kappa lambda light chain &gt; 10 mg/dl . 2 . &gt; =90 day &lt; = 120 day post transplant 3 . Laboratory value less equal 2 week prior initiation treatment : Absolute neutrophil count ( ANC ) great equal 1.5 x 10^9/L Platelets ( PLT ) great equal 100 x 10^9/L Hemoglobin ( Hgb ) great equal 9 g/dL Serum creatinine less equal 1.5 upper limit normal ( ULN ) Serum bilirubin less equal 1.5 ULN Aspartate aminotransferase ( AST/SGOT ) alanine aminotransferase ( ALT/SGPT ) less equal 3.0 x ULN Negative proteinuria base dip stick reading OR , documentation +1 result protein dip stick reading , total urinary albumin â‰¤ 500 mg measure creatinine clearance ( CrCl ) great equal 50 mL/min 24hour urine collection 4 . A negative pregnancy test 48 hour prior study treatment must lactate female childbearing age . 5 . Ability understand willingness sign write informed consent document accordance guideline Washington University Human Studies Committee . 6 . Age great equal 18 year old . 7 . ECOG performance status less equal 2 . 1 . Receiving investigational agent . 2 . Receiving concurrent steroid dose equivalent prednisone &gt; = 150 mg/month . 3 . Female patient pregnant breast feeding , adult reproductive potential employ effective method birth control . Barrier contraceptives must use throughout trial sex . Oral , implantable , injectable contraceptive may affect cytochrome P450 interaction , therefore consider effective study . 4 . Biopsy proven amyloidosis . 5 . Patients history another primary malignancy within less equal 5 year , exception inactive basal squamous cell carcinoma skin . 6 . Prior chemotherapy less equal 3 week prior registration and/or randomization . Patients must recover therapyrelated toxicity . 7 . Prior biologic immunotherapy less equal 2 week prior registration and/or randomization . Patients must recover therapyrelated toxicity . 8 . Prior full field radiotherapy less equal 4 week limited field radiotherapy less equal 2 week prior randomization . Patients must recover therapyrelated toxicity . 9 . Pleural effusion ascites cause respiratory compromise ( great equal CTC grade 2 dyspnea ) . 10 . Major surgery ( i.e . laparotomy ) less equal 4 week prior randomization . Minor surgery less equal 2 week prior randomization . Insertion vascular access device consider major minor surgery regard . Patients must recover surgeryrelated toxicity . 11 . Patients receive investigational drug less equal 4 week prior registration and/or randomization . 12 . Prior therapy antivascular endothelial growth factor ( VEGF ) agent . 13 . Any following concurrent severe and/or uncontrolled medical condition could compromise participation study : Uncontrolled high blood pressure , history labile hypertension , history poor compliance antihypertensive regimen Unstable angina pectoris Symptomatic congestive heart failure Myocardial infarction less equal 6 month prior registration and/or randomization Serious uncontrolled cardiac arrhythmia QTc interval &gt; 450 millisecond male &gt; 470 millisecond female Uncontrolled diabetes Active uncontrolled infection Interstitial pneumonia extensive symptomatic interstitial fibrosis lung 14 . Acute chronic liver disease ( e.g . hepatitis , cirrhosis ) . 15 . Impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption PTK787/ZK 222584 ( i.e. , ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome , bowel obstruction , inability swallow tablet ) . 16 . Patients confirm diagnosis human immunodeficiency virus ( HIV ) infection exclude investigator 's discretion he/she feel : potential drug interaction PTK787/ZK 222584 patient 's antiHIV medication could influence efficacy antiHIV medication , may place patient risk due pharmacologic activity PTK787/ZK 222584 . 17 . Patients take therapeutic warfarin sodium ( Coumadin ) similar oral anticoagulant metabolize cytochrome P450 system . Heparin allow . 18 . Patients unwilling unable comply protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Myeloma</keyword>
	<keyword>PTK</keyword>
</DOC>